Bladder Cancer
Specialty Channel

Featured Article
The FDA granted accelerated approval to sacituzumab govitecan to treat adult patients with locally advanced or metastatic urothelial cancer (mUC), who have previously received a platinum-containing…
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
True or False: Pembrolizumab provided a durable clinical response in cisplatin-ineligible patients with advanced urothelial carcinoma and is associated with prolonged OS.
Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.
The FDA approved avelumab for the first-line maintenance treatment of patients with locally advanced metastatic or urothelial carcinoma who have not progressed on first-line platinum-containing…
True or False: Enfortumab vedotin monotherapy has not been shown to yield durable responses in patients with metastatic urothelial cancer.
The FDA extended the indication of gemtuzumab ozogamicin to include newly diagnosed CD33-positive AML in patients aged 1 month and older.

News

The FDA granted accelerated approval to sacituzumab govitecan to treat adult patients with locally advanced or metastatic urothelial cancer (mUC), who have previously received a platinum-containing…
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.
The FDA approved avelumab for the first-line maintenance treatment of patients with locally advanced metastatic or urothelial carcinoma who have not progressed on first-line platinum-containing…

Interactive Features

What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
True or False: Pembrolizumab provided a durable clinical response in cisplatin-ineligible patients with advanced urothelial carcinoma and is associated with prolonged OS.
True or False: Enfortumab vedotin monotherapy has not been shown to yield durable responses in patients with metastatic urothelial cancer.
Stay in the know.
OncNet Newsletter